Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039000 · ClinicalTrials.gov registry record · Phase 3
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
A Phase 3 study, sponsored by Agenus.
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT00039000 is a Phase 3 study that has completed, run by Agenus. The registered enrollment target is 350 participants.
The verdict
NCT00039000, a Phase 3 study, has completed, sponsored by Agenus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery but who receive conventional chemotherapy including IL-2/DTIC. A second goal is to determine the safety and frequency of side effects in subjects who receive therapy with HSPPC-96.
Interventions
- DRUG HSPPC-96 or Oncophage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2002-03 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039000
The ClinicalTrials.gov registry entry for NCT00039000 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HSPPC-96 or Oncophage is the first listed.
NCT00039000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039000 about?
NCT00039000 is a clinical study titled "Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma". The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery but who receive conventional chemotherapy including IL-2/DTIC. A second ...
What is the current status of trial NCT00039000?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2002-03. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00039000?
The interventions under investigation include: HSPPC-96 or Oncophage (DRUG).
Who is sponsoring clinical trial NCT00039000?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.